Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection

References

• Centers for disease control and prevention. estimated HIV incidence in the United States, 2007-2010. HIV surveillance supplemental report. 2012.17(4). Available from: www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf [Last accessed 21 March 2015]
   Google Scholar
• Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data – United States and 6 dependent areas – 2011. HIV surveillance supplemental report. 2013.18(5). Available from: www.cdc.gov/hiv/pdf/2011_monitoring_hiv_indicators_hssr_final.pdf [Last accessed 21 March 2015]
   Google Scholar
• Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135(1):17-26
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med 2011;365(6):493-505
   PubMed Web of Science ®Google Scholar
• Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010;24(1):123-37
   PubMed Web of Science ®Google Scholar
• Isentress^® (raltegravir) [package insert]. Merck Sharp and Dohme, Corp; Whitehouse Stations, NJ: 2014
   Google Scholar
• Vitekta^® (elvitegravir) [package insert]. Gilead Sciences, Inc; Foster City, CA: 2014
   Google Scholar
• StribildTM (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [package insert]. Gilead Sciences, Inc; Foster City, CA: 2012
   Google Scholar
• Tivicay^® (dolutegravir) [package insert]. ViiV Healthcare; Research Triangle Park, NC: 2014
   Google Scholar
• Triumeq^® (abacavir, dolutegravir, and lamivudine) [Package insert]. ViiV Healthcare; Research Triangle Park, NC: 2014
   Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48 week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-33
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Markowitz M, Ratanasuwan W, et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr 2012;61(1):73-7
   PubMed Web of Science ®Google Scholar
• Young B, Vanig T, Dejesus E, et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48 week results of the SHIELD trial. HIV Clin Trials 2010;11(5):260-9
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5 year results from STARTMRK. J Acquir Immune Defic Syndr 2013;63(1):77-85
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359(4):339-54
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013;13(7):587-96
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Libre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPRIAL study. AIDS 2010;24(11):1697-707
   PubMed Web of Science ®Google Scholar
• Gallien S, Braun J, Delaugerre C, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011;66(9):2099-106
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve subjects: 96 week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013;29(2):256-65
   PubMed Web of Science ®Google Scholar
• Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS ONE 2014;9(8):e106221
   PubMed Web of Science ®Google Scholar
• Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014;384(9958):1942-51
   PubMed Web of Science ®Google Scholar
• Boyd MA, Kumarasamy N, Moore CL, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013;381(9883):2091-9
   PubMed Web of Science ®Google Scholar
• Amin J, Boyd MA, Kumarasamy N, et al. Raltegravir non-inferior to nucleoside based regimens in SECOND-LINE therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection. PLoS One 2015;10(2):e0118228
   Web of Science ®Google Scholar
• Gantner P, Koeppel C, Partisani M, et al. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scand J Infect Dis 2014;46(12):838-45
   PubMed Web of Science ®Google Scholar
• Monteiro P, Perez I, Laguno M, et al. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother 2014;69(3):742-8
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22(14):1890-2
   PubMed Web of Science ®Google Scholar
• Croce F, Vitello P, Dalla Pria A, et al. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS 2010;21(11):783-5
   PubMed Web of Science ®Google Scholar
• Tsai WJ, Lee SS, Tsai HC, et al. Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen. J Microbiol Immunol Infect 2013;pii:S1684-1182(13):00034-0
   Google Scholar
• Isentress® (raltegravir) tablet. Detailed view: safety labeling changes approved by FDA enter for Drug Evaluation and Research (CDER). Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm122184.htm [Last accessed 8 March 2015]
   Google Scholar
• Zhang KS, Modi GM, Hsu S. DRESS syndrome associated with raltegravir. Dermatol Online J 2011;17(8):14
   PubMedGoogle Scholar
• Loulergue P, Mir O. Raltegravir-induced DRESS syndrome. Scand J Infect Dis 2012;44(10):802-3
   PubMed Web of Science ®Google Scholar
• Perry ME, Almaani N, Desai N, et al. Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safety. Int J STD AIDS 2013;24(8):639-42
   PubMed Web of Science ®Google Scholar
• Yee BE, Nguyen NH, Lee D. Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV. BMJ Case Rep 2014;2014
   PubMedGoogle Scholar
• Calza L, Danese I, Colangeli V, et al. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. AIDS Res Hum Retroviruses 2014;30(12):1162-9
   PubMed Web of Science ®Google Scholar
• Lee FJ, Amin J, Bloch M, et al. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr 2013;62(5):525-33
   PubMed Web of Science ®Google Scholar
• Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents 2015;45(3):289-94
   PubMed Web of Science ®Google Scholar
• Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014;58(3):423-31
   PubMed Web of Science ®Google Scholar
• Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010;55(2):148-55
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379(9835):2429-38
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379(9835):2439-48
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;63(1):96-100
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65(3):e118-20
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;62(5):483-6
   PubMed Web of Science ®Google Scholar
• Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65(3):e121-4
   PubMed Web of Science ®Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12(1):27-35
   PubMed Web of Science ®Google Scholar
• Elion R, Molina JM, Ramon Arribas Lopez J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr 2013;63(4):494-7
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014;14(7):581-9
   PubMed Web of Science ®Google Scholar
• Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis 2014;14(7):590-9
   PubMed Web of Science ®Google Scholar
• Mills A, Crofoot G, Ortiz R, et al. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials 2014;15(2):51-6
   PubMed Web of Science ®Google Scholar
• Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312(4):410-25
   PubMed Web of Science ®Google Scholar
• Van Wesenbeeck L, Rondelez E, Feyaerts M, et al. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother 2011;55(1):321-5
   PubMed Web of Science ®Google Scholar
• Abram ME, Hluhanich RM, Goodman DD, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013;57(6):2654-63
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013;13:927-35
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369(19):1807-18
   PubMed Web of Science ®Google Scholar
• Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label 3b study. Lancet 2014;383(9936):2222-31
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak A, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral- experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised double- blind, non-inferiority SAILING study. Lancet 2013;382(9893):700-8
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014;210(3):354-62
   PubMed Web of Science ®Google Scholar
• Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther 2015;20(3):343-8
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naïve HIV-infected individuals in three randomized trials. AIDS 2015;29(2):167-74
   PubMed Web of Science ®Google Scholar
• Patel DA, Snedecor SJ, Tang WY, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naïve HIV-1-infected patients: a systemic review and network meta-analysis. PLoS One 2014;9(9):e105653
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink H, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381(9868):735-43
   PubMed Web of Science ®Google Scholar
• Curtis L, Nicholas G, Stainsby C, et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naïve patients. HIV Clin Trials 2014;15(5):199-208
   PubMed Web of Science ®Google Scholar
• Thompson AB, Wynn BA, O Akerele D, et al. Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration. AIDS 2015;29(3):390-2
   PubMed Web of Science ®Google Scholar
• Mesplède T, Wainberg MA. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 2014;6(9):3377-85
   PubMed Web of Science ®Google Scholar
• Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase–DNA complexes. Antimicrob Agents Chemother 2011;55(10):4552-9
   PubMed Web of Science ®Google Scholar
• DeAnda F, Hightower KE, Nolte RT, et al. Dolutegravir interactions with HIV-1 integrase–DNA: structural rationale for drug resistance and dissociation kinetics. PLoS ONE 2013;8(10):e77448
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimirob Agents Chemother 2011;55(2):813-21
   PubMed Web of Science ®Google Scholar
• Underwood MR, Johns BA, Sato A, et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012;61(3):297-301
   PubMed Web of Science ®Google Scholar
• Quashie PK, Mesplède T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012;86(5):2696-705
   PubMed Web of Science ®Google Scholar
• Munir S, Thierry E, Malet I, et al. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemother 2015;70(3):739-49
   PubMed Web of Science ®Google Scholar
• Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011;204(11):1811-15
   PubMed Web of Science ®Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013;207(5):740-8
   PubMed Web of Science ®Google Scholar
• Cavalcanti Jde S, Ferreira JL, Guimarães PM, et al. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen. J Antimicrob Chemother 2015;70(3):926-9
   PubMed Web of Science ®Google Scholar
• Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1 infected patients. J Antimicrob Chemother 2015;70(5):1507-12
   PubMed Web of Science ®Google Scholar
• Hardy I, Brenner B, Quashie P, et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 2015;70(2):405-11
   PubMed Web of Science ®Google Scholar
• Eron JJJr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS). Guidelines version 7.1. Available from: www.eacsociety.org/files/guidelines-7.1-english.pdf
   Google Scholar
• Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 2014;67(5):481-6
   PubMed Web of Science ®Google Scholar
• Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 2014;67(5):487-92
   PubMed Web of Science ®Google Scholar
• Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013;14(5):192-203
   PubMed Web of Science ®Google Scholar
• Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir and rilpivirine as two-drug oral maintenance therapy: LATTE week 96 results Poster number 554LB. Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI); 23 – 26 February 2015; Seattle, Washington
   Google Scholar
• Fenwick C, Amad M, Bailey MD, et al. Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimirob Agents Chemother 2014;58(6):3233-44
   PubMed Web of Science ®Google Scholar
• Aslanyan S, Ballow CH, Sabo JP, et al. Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers Presentation number A1-1725. Poster presented at 41st Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2011; Chicago, IL
   Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385(9987):2606-15
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53(8):807-16
   PubMed Web of Science ®Google Scholar
• Minami R, Yamamoto M, Takahama S, et al. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother 2011;17(2):183-8
   PubMed Web of Science ®Google Scholar
• Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Neutral actions of raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res 2011;9(3):174-9
   PubMed Web of Science ®Google Scholar
• De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009;49:1259-67
   PubMed Web of Science ®Google Scholar